Please login to the form below

Not currently logged in
Email:
Password:

ChemoCentryx

This page shows the latest ChemoCentryx news and features for those working in and with pharma, biotech and healthcare.

ChemoCentryx surges on phase 3 vasculitis study

ChemoCentryx surges on phase 3 vasculitis study

ChemoCentryx’ complement C5a inhibitor avacopan has outperformed standard corticosteroid therapy in a phase 3 vasculitis trial, causing a spike in its share price and analyst speculation it may have a blockbuster ... ChemoCentryx’ chief executive

Latest news

  • GSK hands back rights to ChemoCentryx drug GSK hands back rights to ChemoCentryx drug

    GSK licensed rights to vercirnon (also known as Traficet-EN and CCX282) in 2010 as an extension to a wide-ranging deal with ChemoCentryx for four anti-inflammatory drugs. ... GSK dropped another drug from the initial collaboration earlier this year, but

  • Takeda files IBD drug vedolizumab in Europe Takeda files IBD drug vedolizumab in Europe

    Growth for vedolizumab and other new entrants such as Johnson &Johnson's interleukin-23 inhibitor Stelara (ustekinumab) and GlaxoSmithKline/ChemoCentryx' vercirnon in Crohn's - and Pfizer's JAK inhibitor tofacitinib in

  • GSK to tackle inflammatory bowel disease

    GSK has exercised an option to further develop ChemoCentryx's Traficet-EN (CCX282-B)  for the treatment of inflammatory bowel disease. ... Under the terms of the collaboration, ChemoCentryx will receive an option exercise fee of $35m and may be

  • Pharma news in brief

    ChemoCentryx will receive an upfront payment of $63.5m in both cash and an equity investment. ... The collaboration covers several projects, including ChemoCentryx's drug, Traficet-EN, which is already in late-stage development for inflammatory bowel

  • A bright start

    The group has formed a strategic alliance with US-based ChemoCentryx to develop and market treatments for various inflammatory disorders in a licensing deal that could be worth up to ... ChemoCentryx is to receive an upfront $63.5m payment comprising

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    In an expansion of their May 2016 licence, Vifor Pharma has gained additional territorial rights from ChemoCentryx to avacopan, a phase III oral inhibitor of the complement 5a receptor (C5aR) for ... In return for the expanded territory, Vifor is paying

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics